Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07213609 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
A Phase 1 study of Neoplasms and Neoplasms, Colorectal, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 9
- Study locations
NCT07213609 is a Phase 1 study of Neoplasms and Neoplasms, Colorectal that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 47 participants, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The trial reports 9 study locations across 5 states.
The verdict
NCT07213609, a Phase 1 study of Neoplasms and Neoplasms, Colorectal, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 9
- Study locations
Study Summary
Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential combinations may be included in future amendments to the protocol) with other anti-cancer agents can decrease tumor size, is safe, well-tolerated, and how the drug is processed in the body over time.
Conditions Studied
Interventions
- DRUG GSK5460025
Study Locations (9)
Other
- GSK Investigational Site - Chiba
- GSK Investigational Site - Osaka
- GSK Investigational Site - Tokyo
- GSK Investigational Site - Tokyo
Ontario
- GSK Investigational Site - Hamilton
- GSK Investigational Site - Toronto
Ohio
- GSK Investigational Site - Canton
Tennessee
- GSK Investigational Site - Nashville
Quebec
- GSK Investigational Site - Montreal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2025-10-20 |
| Est. Completion | 2028-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07213609
The ClinicalTrials.gov registry entry for NCT07213609 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,621-participant average among 158 other Neoplasms trials with a reported enrollment target (97% lower). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which GSK5460025 is the first listed.
NCT07213609 reports 9 study locations spanning 5 distinct geographic areas - top geographies include Other, Ontario, Ohio.
Frequently Asked Questions
What is clinical trial NCT07213609 about?
NCT07213609 is a clinical study titled "A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors". Solid tumours are abnormal lumps of tissue that can occur in different parts of the body. The tumours involved in this study have specific genetic characteristics that can make them more aggressive and challenging to treat. The study will test whether GSK5460025 alone or in combination (potential co...
What is the current status of trial NCT07213609?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2025-10-20. Estimated completion is 2028-10-27.
What conditions does trial NCT07213609 study?
This clinical trial studies the following conditions: Neoplasms, Neoplasms, Colorectal.
What interventions are being tested in trial NCT07213609?
The interventions under investigation include: GSK5460025 (DRUG).
Who is sponsoring clinical trial NCT07213609?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07213609 being conducted?
This trial has 9 study locations across Ohio, Tennessee, Ontario, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s)
RECRUITING · Phase 1
-
A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)
RECRUITING · Phase 1
-
Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
RECRUITING · Phase 1
-
Two Part Study of Nenocorilant Combined With Nivolumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers
RECRUITING · Phase 1
-
Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.